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Hospitalized patientsAbstract The objective of this study was to investigate the inﬂuence of simultaneous factors that
potentially keep patients far from achieving target INR range at discharge in hospitalized patients.
Prospective cross-sectional observational study conducted at the Cardiology Department and
Intensive Care Unit (ICU) of the Assiut University Hospitals. One-hundred and twenty patients
were enrolled in the study from July 2013 to January 2014. Outcome measures were discharge
INRs, bleeding and thromboembolic episodes. Bivariate analysis and multinomial logistic regres-
sion were conducted to determine independent risk factors that can keep patients outside target
INR range.
Patients who were newly initiated warfarin on hospital admission were given low initiation dose
(2.8 mg ± 0.9). They were more likely to have INR values below 1.5 during hospital stay, 13
(27.7%) patients compared with 9 (12.3%) previously treated patients, respectively (p= .034).
We found that the best predictors of achieving below target INR range relative to within target
INR range were; shorter hospital stay periods (OR, 0.82 for every day increase [95% CI, 0.72–
0.94]), being a male patient (OR, 2.86 [95% CI, 1.05–7.69]), concurrent infection (OR, 0.21 [95%
CI, 0.07–0.59]) and new initiation of warfarin therapy on hospital admission (OR, 3.73 [95% CI,
1.28–10.9]).
Gender, new initiation of warfarin therapy on hospital admission, shorter hospital stay periods
and concurrent infection can have a signiﬁcant effect on discharge INRs. Initiation of warfarin
without giving loading doses increases the risk of having INRs below 1.5 during hospital stay
Factors inﬂuencing warfarin response in patients 643and increases the likelihood of a patient to be discharged with INR below target range. Following
warfarin dosing nomograms and careful monitoring of the effect of various factors on warfarin
response should be greatly considered.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Warfarin has been utilized as an anticoagulant drug for about
60 years but still causing a variety of adverse effects.
Routinely, warfarin is monitored by measuring the
International Normalized Ratio (INR). The target INR range
for most indications of warfarin therapy is 2–3 or 2.5–3.5
(Keeling et al., 2011; Holbrook et al., 2012). Keeping patients
within target INR range is a challenge. A number of world-
wide studies have been conducted to examine the response to
warfarin therapy in both ambulatory and hospital settings
(Doecke et al., 1991; Brigden et al., 1998; Fang et al., 2006;
Clark et al., 2014). Response to warfarin therapy is patient
speciﬁc; however, various factors have been reported to alter
warfarin response and target INR such as older age, disease
states, warfarin dose and inﬂuence of other medications
(Doecke et al., 1991; Brigden et al., 1998; Demirkan et al.,
2000; Hylek et al., 2001; Froom et al., 2003; Torn et al.,
2005; Fang et al., 2006; Clark et al., 2014). Conﬂicting results
have been reported for some of these factors such as age, gen-
der and concurrent disease states (Fihn et al., 1996; Demirkan
et al., 2000; Sivrikaya et al., 2013). The presence of these fac-
tors can keep patients away from achieving target INR range
and may cause unnecessary complications. Consequently,
monitoring and watching for these inﬂuential factors is essen-
tial. The objective of this study was to report on the degree to
which various factors can hinder achieving target INR range in
a sample of adult Egyptian patients on their discharge from
hospital care setting.
2. Methods
2.1. Study design and settings
This prospective cross-sectional observational study was con-
ducted at Cardiology Department and Intensive Care Unit
(ICU) of Assiut University Hospitals. The study was approved
by the Research Ethics Committee at the Faculty of Medicine
of Assiut University.
2.2. Study participants
All patients admitted to the Cardiology Department and ICU
of Assiut University Hospitals and received warfarin anticoa-
gulation therapy, from July 2013 till January 2014, were
included in the study.
2.3. Data collection
Patients’ data regarding warfarin anticoagulation therapy were
collected by reviewing patients’ medical records, laboratory
measurements of INR and when necessary by interviewinghealth care professionals as well as patients when some data
were missing. Actual warfarin usage and INR measuring lab-
oratories were monitored for one month before designing
and formulating data collection sheets.
2.4. Data analysis
All statistical analyses were performed using IBM SPSS v. 22.
Data are presented as mean (standard deviation), median
(interquartile range) or proportions as appropriate. A p-value
of less than 0.05 was considered signiﬁcant for all comparisons
and all tests were two-tailed.
Independent sample t-test with bootstrap was used to com-
pare mean difference between two unrelated groups. Non-
parametric tests; Mann–Whitney U test and Kruskal Wallis
H test were used to ﬁnd difference in discharge INRs within
the different groups.
Pearson and spearman’s rank correlations with bootstrap
were used to examine associations between groups.
Multinomial logistic regression was used to examine the
inﬂuence of different factors on the state of discharge INRs
(below, above and within target range groups).
3. Results
3.1. Baseline characteristics
Table 1 shows baseline patients’ characteristics. A total of 120
patients were admitted to the Cardiology Department and the
ICU. Their mean age was 48.35 years. Seventy-one (59.2%)
patients were females. The majority of patients 83 (69.2%)
were non-educated, and only 9 (7.5%) patients ﬁnished univer-
sity education. One hundred patients (83.3%) were admitted to
the Cardiology Department. Warfarin was most commonly
prescribed for atrial ﬁbrillation, 66 (55%) patients.
3.2. Warfarin management metrics
Table 2 shows warfarin management metrics for the patients.
Seventy-three patients were previously treated with warfarin
before hospital admission and 47 (39.2%) patients were newly
initiated warfarin on hospital admission. Prescribed dose,
admission and discharge INRs were signiﬁcantly higher for
patients previously treated with warfarin.
3.3. Warfarin prescribed dose in different patient groups
Table 3 shows difference in prescribed warfarin doses in differ-
ent patient groups. Elderly patients (P60 years) and patients
with congestive heart failure were given lower mean prescribed
doses than other patients. Patients with mechanical valve
replacement were given higher mean prescribed dose than
Table 1 Patients’ baseline characteristics.
Total number of the patients 120 (100%)
Mean age 48.4 ± 15.5
Sex
Males 49 (40.8%)
Females 71 (59.2%)
Education
Non-educated 83 (69.2%)
Primary education 17 (14.2%)
Vocational education 11 (9.2%)
University education 9 (7.5%)
Place of admission
Cardiology department 100 (83.3%)
Cardiovascular Intensive Care Unit 20 (16.7%)
Indication for warfarin therapy
Atrial Fibrillation 66 (55%)
Mechanical valve replacement 11 (9.2%)
MVR 5
AVR 1
DVR 5
Cardiomyopathy 13 (10.8%)
Thromboembolism 5 (4.2%)
DVT 3
PE 2
Myocardial infarction 4 (3.3%)
Stroke 1 (0.8%)
Multiple conditions 17 (14.2%)
Other conditions 3 (2.5%)
MVR: mitral valve replacement, AVR: atrial valve replacement,
DVR: double valve replacement, DVT: deep venous thrombosis,
PE: pulmonary embolism. Other conditions refer to clinical indi-
cations rather than reported in the table.
644 M.I. Abdel-Aziz et al.other patients. In patients who were previously treated with
warfarin, age was signiﬁcantly related to current warfarin dose
(maintenance dose), r= .31, 95% BCa CI [.5, .08],
p= .008.
3.4. Risk of bleeding from warfarin
Ten patients suffered from bleeding during hospital stay. All
bleeding episodes were considered minor or minimal such as
epistaxis, hemoptysis, hematemesis and rectal bleeding. Out
of the 10 patients, 2 patients were P65 years (p= .69), 2Table 2 Warfarin management metrics.
Patients previously treated with
warfarin n= 73 (60.8%)
Mean (standard deviation)
Prescribed dosec 4.1 mg (±2.2)
Discharge dose 4 mg (±2.6)
Days of hospital stay 9.2 days (±5)
Number of INR measurements 3.4 (±2.8)
Admission INRs 2.7 (±2.2)
Discharge INRs 2.9 (±1.9)
BCa 95% CI: Bias corrected and accelerated 95% conﬁdence interval.
a Signiﬁcant at p< .05.
b Signiﬁcant at p< .01, bootstrap for independent samples t-test based
c Prescribed dose means current dose for previously treated warfarin phad congestive heart failure (p= .016) and 6 had liver disease
(p= .003).
3.5. State of discharge INRs
Table 4 shows the description of median and interquartile
ranges of discharge INR values and analysis of factors poten-
tially affecting them. Newly initiated warfarin patients 27
(22.5%), were more likely to have discharge INR values below
target range compared with previously treated patients 24
(20%) (p= .012). Also, newly initiated warfarin patients were
more likely to have INR values below 1.5 during hospital stay,
13 (27.7%) patients compared with 9 (12.3%) patients respec-
tively (p= .034). Of the newly initiated warfarin patients, one
patient suffered from new thrombus formation during hospital
stay and 6 (5%) patients had INR values P5 during hospital
stay compared with 8 (6.7%) previously treated warfarin
patients (p= .76).
The number of weeks of hospital stay was signiﬁcantly
related to discharge INRs, rs = .25. 95% BCa CI [.05–.42],
p= .008.
Out of 22 hypertensive patients, 12 (54.6%) were newly
initiated warfarin on hospital admission (p= .1). Out of the
76 patients who had rheumatic heart disease, 54 (71.1%)
patients were previously treated with warfarin (p= .003).
Stepwise comparison using Kruskal–wallis test showed that
patients with multiple conditions and mechanical valve
replacement had signiﬁcantly higher median discharge INR
compared with other indications of warfarin therapy.
Similarly, it showed that patients who were admitted from 2
to 63 weeks and P3 weeks had signiﬁcantly higher median
discharge INR values compared with patients admitted for less
than 2 weeks.
Out of 52 (43.3%) patients who had infection; 21 (17.5%)
patients suffered from active rheumatic heart disease, 15
(12.5%) patients suffered from chest infection, 13 (10.8%)
patients suffered from infective endocarditis and 3 (2.5%)
patients suffered from urinary tract infection.
3.6. Multinomial logistic regression of factors that potentially
affect discharge INRs
Multinomial logistic regression whereby clinical and other
patient characteristics were included in the model (Table 5)Patients newly initiated
warfarin on hospital
admission n= 47 (39.2%)
p-Value BCa 95% CI
2.8 mg (±0.9) .001b 0.76, 1.86
3.5 mg (±1.2) .16 0.18, 1.28
10 days (±8.3) .56 3.77, 1.98
3.7 (±4.4) .64 2.09, 1.12
1.3 (±0.3) .001b 0.90, 1.92
2.2 (±1.5) .02a 0.07, 1.34
on 1000 bootstrap samples..
atients and initiation dose for newly initiated warfarin patients.
Table 3 Comparing the mean prescribed warfarin doses between study groups.
Character Number of patients (%) N= 120 (100%) Mean prescribed dose (SD) p-Value BCa 95% CI
Age .004a 1.55, 0.34
AgeP 60 29 (24.2%) 2.9 (±1.1)
Age < 60 91 (75.8%) 3.8 (±2.1)
Mechanical valve replacementb .002a 1.23, 3.11
Yes 25 (20.8%) 5.3 (±2.6)
No 95 (79.2%) 3.2 (±1.4)
Congestive heart failure .003a 1.96, 0.61
Yes 70 (58.3%) 3.1 (±1.5)
No 50 (41.7%) 4.3 (±2.2)
BCa 95% CI: Bias corrected and accelerated 95% conﬁdence interval.
a Signiﬁcant at p< .01, bootstrap for independent samples t-test based on 1000 bootstrap samples.
b All patients with mechanical valve replacement including those with multiple conditions.
Table 4 Factors that potentially affect median and interquartile ranges of the discharge INR values.
Character Number of patients (%) N= 120 Median INR (IQR) p-Value
Sex .27
Male 49 (40.8%) 1.9 (1.5–2.5)
Female 71 (59.2%) 2.1 (1.6–3.1)
Age category .29
Young 2 (1.7%) 3.4
Adult 89 (74.2%) 2.1 (1.6–3)
Elderly 29 (24.2%) 1.8 (1.4–3)
Education .12
Non-educated 83 (69.2%) 2.1 (1.5–3.1)
Primary education 17 (14.2%) 2.2 (1.8–2.8)
Vocational education 11 (9.2%) 3.3 (1.9–3.7)
University education 9 (7.5%) 1.6 (1.2–2.1)
Place of admission .88
Cardiovascular Department 100 (83.3%) 2.1 (1.6–2.9)
Cardiovascular ICU 20 (16.7%) 2.2 (1.3–3.1)
Indication for warfarin therapy .01a
Atrial Fibrillation 66 (55%) 1.9 (1.5–2.7)
Mechanical valve 11 (9.2%) 2.6 (2.3–3.5)
Cardiomyopathy 13 (10.8%) 1.7 (1.4–2.2)
Thromboembolism 5 (4.2%) 1.8 (1.7–8.8)
MI 4 (3.3%) 1.7 (1.2–2)
Multiple conditions 17 (14.2%) 3.1 (2.1–4.4)
Other conditions 3 (2.5%) 2.6
Number of weeks of hospital stay .024a
<1 week 45 (37.5%) 1.9 (1.3–2.7)
1–<2 55 (45.8%) 2.1 (1.6–2.8)
2–<3 14 (11.7%) 2.4 (1.9–4.1)
P3 6 (5%) 3.8 (2.4–4.4)
State of warfarin therapy .001b
Previously treated 73 (60.8%) 2.3 (1.8–3.4)
Newly initiated 47 (39.2%) 1.7 (1.3–2.3)
Comorbidities
Hypertension 22 (18.3%) 1.7 (1.2–2.5) vs. 2.1 (1.6–3.1) .038a
Diabetes mellitus 23 (19.2%) 1.7 (1.3–2.9) vs. 2.1 (1.6–3) .13
Congestive heart failure 70 (58.3%) 1.9 (1.4–2.3) vs. 2.6 (1.7–4) .006b
Rheumatic heart disease 76 (63.3%) 2.3 (1.7–3.2) vs. 1.7 (1.4–2.3) .006b
Non-rheumatic valvular heart disease 10 (8.3%) 1.7 (1.2–2.5) vs. 2.1 (1.6–3) .14
Ischemic heart disease 20 (16.7%) 1.7 (1.3–2.3) vs. 2.1 (1.6–3.1) .05
Liver disease 23 (19.2%) 2.1 (1.3–2.6) vs. 2.1 (1.5–3) .62
Infection 52 (43.3%) 2.38 (1.9–3.6) vs. 1.8 (1.4–2.4) .004b
Other comorbid conditions 43 (35.8%) 2.1 (1.6–3) vs. 2.1 (1.5–2.9) .79
p-values were generated using non-parametric tests (Mann–Whitney U and Kruskal Wallis tests) as appropriate.
IQR: interquartile range, ICU: Intensive Care Unit, MI: myocardial infarction.
a Signiﬁcant at p< .05.
b Signiﬁcant at p< .01.
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Table 5 Potential factors affecting state of discharge INR values: multivariate multinomial logistic regression.
Predictor Beta (SE) 95% CI for odds ratio
Lower Odds ratio Upper
Below target range vs. within target range
Intercept 0.69 (1.39)
Age 0.02 (0.02) 0.99 1.02 1.05
Prescribed warfarin dose 0.18 (0.14) 0.9 1.19 1.58
Days of hospital stay 0.2 (0.07)b 0.72 0.82 0.94
Gender (female vs. male) 1.06 (0.51)a 0.13 0.35 0.95
Congestive heart failure 0.54 (0.55) 0.58 1.72 5.08
Liver disease 0.09 (0.67) 0.3 1.1 4.05
Infection 1.58 (0.54)b 0.07 0.21 0.59
State of warfarin therapy (newly initiated vs. previously treated patients) 1.32 (0.55)a 1.28 3.73 10.9
Above target range vs. within target range
Intercept 1.66 (1.64)
Age 0.01 (0.02) 0.96 1.01 1.05
Prescribed warfarin dose 0.08 (0.15) 0.8 1.08 1.46
Days of hospital stay 0.11 (0.06)a 1 1.12 1.24
Gender (female vs. male) 0.31 (0.6) 0.23 0.73 2.39
Congestive heart failure 0.58 (0.6) 0.17 0.56 1.81
Liver disease 0.98 (0.83) 0.07 0.37 1.88
Infection 0.19 (0.59) 0.37 1.21 3.89
State of warfarin therapy (newly initiated vs. previously treated patients) 0.45 (0.74) 0.15 0.64 2.73
Note. Within target range group was used as the reference groups. R2 = .351 (Cox & Snell), .401 (Nagelkerke). Model v2(16) = 49.37, p< .001.
a p< .05.
b p< .01.
646 M.I. Abdel-Aziz et al.showed that the best predictors of achieving below target INR
range relative to within target INR range were; shorter hospi-
tal stay periods (0.82 times less likely for every day increase,
p= .006), being a male patient (2.85 times more likely,
p= .039), infection (0.21 times less likely, p= .003) and
patients newly initiated warfarin therapy on hospital admis-
sion (3.73 times more likely, p= .016).
Whereas, the best predictor of achieving above target rela-
tive to within target INR values was; longer duration of hospi-
tal stay (1.12 times more likely for every day increase,
p= .048).
4. Discussion
The present study investigated the potential effect of various
factors on warfarin response.
We observed that warfarin initiation dose was not pre-
scribed according to the guidelines. The starting dose of the
majority of patients who were newly initiated warfarin in the
hospital was 3 mg. Doses lower than 3 mg were initiated in
the elderly (>70 years) and liver disease patients. When initiat-
ing warfarin therapy, loading dose is usually given to rapidly
elevate INR and reduce the time needed to achieve target
INR range. Studies have suggested that warfarin initiation
dose between 5 and 10 mg is appropriate and effective
(Ageno et al., 2012). Some studies have suggested that 10 mg
loading dose is not superior to 5 mg loading dose and that
5 mg dose may avoid the development of potential hyper-
coagulate state (Harrison et al., 1997; Crowther et al., 1999).
However, other studies recommended 10-mg dosing nomo-
gram over 5-mg nomogram because it allowed more rapid
achievement of target INR and it was safe (Kovacs et al.,
2003; Monkman et al., 2009). Initiation dose 65 mg is appro-
priate in the elderly, patients with liver disease, impairednutrition, congestive heart failure and in patients with
increased risk of bleeding (Gurwitz et al., 1992; Garcia et al.,
2005; Ageno et al., 2012). This may explain why newly initiated
warfarin patients were more likely to have discharge INR val-
ues below target range than those who previously initiated it.
This may also explain why newly initiated warfarin patients
were more likely to have INR values below 1.5 during hospital
stay. It was reported that values of INR below 1.5 increase the
risk of thromboembolism (Rose et al., 2009; Nordstrom et al.,
2010).
Elderly patients (P60 years) had lower median INR than
adult and young patients. Although the results were not sta-
tistically signiﬁcant, our data were inconsistent with published
studies. In a USA study conducted on 530 patients, the pro-
thrombin time ratio, when adjusted for dose, was signiﬁcantly
increased in older patients (Gurwitz et al., 1992). Moreover,
older age was found in a number of studies to increase the risk
of INR P5 and warfarin-associated bleeding (Froom et al.,
2003; Torn et al., 2005; Fang et al., 2006). However, age did
not appear to be an important determinant of risk for war-
farin-associated bleeding except may be for age P80 years
(Fihn et al., 1996). Low Median INR and low incidence of
bleeding events in our elderly patients are probably due to that
elderly patients were given smaller mean prescribed warfarin
doses than others. In patients who were previously treated with
warfarin, age was signiﬁcantly related to the maintenance dose.
This was consistent with other published studies that older
patients require lower maintenance warfarin doses (Redwood
et al., 1991; Garcia et al., 2005).
Women had a slightly non-signiﬁcant higher median dis-
charge INR compared with men. Women were less likely to
be discharged with INR values below target range. A
retrospective, longitudinal cohort study conducted on 12,006
patients showed that patients with respiratory illness, as well
Factors inﬂuencing warfarin response in patients 647as women, patients with cancer and those with an elevated
baseline INR, are at high risk of anticoagulation and should
have additional INR monitoring (Clark et al., 2014). Other
studies showed that women required lower maintenance doses
of warfarin than men (Absher et al., 2002; Garcia et al., 2005;
Whitley et al., 2007). However, a retrospective study was con-
ducted on 403 males and 403 females found that men had sig-
niﬁcantly higher baseline INR than women in patients without
any known liver disease or anticoagulant medication
(Sivrikaya et al., 2013). The effect of gender on INR values
and warfarin response may require further investigation.
Patients with multiple conditions and mechanical valve
replacement (especially MVR and DVR) had the highest med-
ian discharge INR compared with others. This is probably due
to these patients require higher target INR of 2.5–3.5 com-
pared with others (mainly from 2 to 3). Consequently, they
were given larger mean prescribed warfarin doses to achieve
higher target INR.
Patients who were admitted for more than two weeks had
the highest median INR values. Also, the number of weeks
of hospital stay was signiﬁcantly related to discharge INRs.
Our ﬁnding showed that longer duration of hospital stay
decreased the likelihood of having INR values below target
range and increased the likelihood of having INR values above
target range. This may suggest that longer hospital stay peri-
ods are required to achieve a desired change in the INR values
and patients who were discharged with INR values below tar-
get range did not stay for adequate time to have their INRs
properly adjusted. Moreover, patients who stayed for longer
hospital periods had deteriorated health conditions which
might affect discharge INRs or that they were kept longer to
have their INRs properly adjusted before discharge.
Hypertensive patients had a lower median INR before dis-
charge than other patients. There has been no reported evi-
dence in the literature on the effect of elevated blood
pressure on INR or warfarin pharmacodynamics and
pharmacokinetics. Also, our subjects did not take any antihy-
pertensive medication that can interact with warfarin.
However, the reason for this may be due to the fact that more
than half of hypertensive patients were newly initiated war-
farin on hospital admission. As mentioned before, newly
initiated warfarin patients were more likely to have discharge
INR values below target range than those who previously
initiated it. In general, the use of warfarin is contraindicated
in patients with malignant, severe and uncontrolled hyperten-
sion, due to increased risk of intracerebral hemorrhage.
Warfarin may be needed to be used cautiously and INR should
be monitored more frequently in patients with severe or uncon-
trolled hypertension (MHRA, 2009).
Patients with congestive heart failure had a lower median
discharge INR and a lower incidence of bleeding events com-
pared with other patients. This was not consistent with pub-
lished reports and studies which have demonstrated that
patients with congestive heart failure have increased response
to warfarin therapy and increased risk of bleeding and high
INR (Petitti et al., 1989; Doecke et al., 1991; Hylek et al.,
2001; Self et al., 2006). The suggested mechanism for increased
warfarin response in congestive heart failure patients is proba-
bly due to hepatic congestion and dysfunction (Self et al.,
2006). The liver is the site for the synthesis of vitamin K clot-
ting factors. Oxygen limitation theory is another suggested
mechanism (Le Couteur and McLean, 1998; Hylek et al.,2001). Also, malnutrition is common in congestive heart fail-
ure patients (Carr et al., 1989). This may be associated with
decreased dietary intake of vitamin K. The decreased discharge
INR for congestive heart failure patients in our study was
probably due to that they were given lower mean prescribed
warfarin doses compared with others.
Patients with liver disease were more likely to experience
bleeding episodes during their hospital stay. This was consis-
tent with other published studies where liver disease was
associated with increased risk of hemorrhage (Landefeld
et al., 1987; Zhang et al., 2006). Liver disease is well docu-
mented to affect warfarin response and cause defective
hemostasis and prolongation of prothrombin time
(Donaldson et al., 1969; Mammen, 1992; Demirkan et al.,
2000). As mentioned above, initiation doses of 65 mg are
appropriate for patients with liver disease and signs of bleeding
should be observed and monitored.
Patients with rheumatic heart disease had a higher median
discharge INR compared with other patients. This could be
explained by that most rheumatic heart disease patients were
diagnosed before admission and were previously treated with
warfarin. As mentioned before, previously treated warfarin
patients were more likely to have higher discharge INR values
compared with newly initiated patients. Many of rheumatic
heart disease patients had prosthetic valve replacement (mainly
MVR and DVR). Warfarin was given to these patients target-
ing higher INR values of 2.5–3.5. Thus, rheumatic heart dis-
ease patients were given higher mean prescribed doses than
others to achieve higher target INR values. Also, some patients
with active rheumatic heart disease were given broad spectrum
antibiotic amoxicillin/clavulanate. Isolated cases of increased
INR were seen in patients taking warfarin concurrently with
amoxicillin/clavulanate (Davydov et al., 2003; Johnson et al.,
2005).
Patients with infection had a higher median discharge INR
compared with other patients. They were less likely to be dis-
charged with INR values below target range. All of these
patients received antibiotics and the higher median INR is
probably due to potential interaction of antibiotics with war-
farin. Patients with infective endocarditis were prescribed
amoxicillin/clavulanate for up to 12 g daily. Antibiotics were
reported to potentially interact with warfarin (Glasheen
et al., 2005; Ghaswalla et al., 2012). Another possible reason
is that fever associated with infection increased response of
warfarin by increasing catabolism of vitamin K dependent coa-
gulation factors (Hirsh et al., 2003). Also, there is a potential
interaction between paracetamol prescribed for fever and war-
farin (Hylek et al., 1998; Lopes et al., 2011). A study was con-
ducted on 12,006 patients found that acute upper respiratory
tract infection increases the risk of excessive anticoagulation
independent of antibiotic use (Clark et al., 2014). Patients with
infection should be closely monitored for potential increased
response of warfarin and drug interactions.5. Conclusion
Various factors were found to affect warfarin response. Days
of hospital stay signiﬁcantly predicted whether patients were
discharged with INR values below or above target range rela-
tive to within target range. Gender, concurrent infection and
new initiation of warfarin therapy signiﬁcantly predicted
648 M.I. Abdel-Aziz et al.whether patients were discharged with INR values below tar-
get range relative to within target range. Initiating warfarin
therapy without giving loading doses can decrease the risk of
bleeding events during hospital stay. However, it increases
the incidence of having INR values 61.5 and consequently
increases the risk of new thrombus formation. Also, it
increases the odds for the patients to be discharged with
INR values below target range or can increase the duration
of hospital stay to get the INRs properly adjusted.
Following warfarin dosing nomograms and careful monitoring
of the effect of various factors on warfarin response should be
greatly considered.
6. Limitations
One of the strengths of our study is that we investigated the
simultaneous effect of various factors on warfarin response
in hospitalized patients. But, we were not encountered with
the genetic effect of the subjects. However, previous studies
on the pharmacogenomics of warfarin in the Egyptian commu-
nity were reported which found that genetic factors are impor-
tant determinant of warfarin dose requirement (Shahin et al.,
2011; Bazan et al., 2012).
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